Hexarelin is a six-amino acid peptide that significantly releases growth hormone. Studies have shown that hexarelin is actually more effective and longer lasting than growth hormone releasing hormone (GHRH). It is also known that GHRP-6 has a synergistic effect with GHRH, causing a far greater release than either of these substances alone. By combining GHRP-6 with Hexarelin, a more potent GH releasing peptide combination is created than ever heard of. The potential clinical usefulness of these GH releasing hexapeptides is also reinforced by observations that long-term administration produces elevations in circulating IGF-1 concentrations. Long term treatment with GHRP-6 similarly has been shown to elevate serum IGF-1 as well as IGF-binding protein-3 concentrations, alter body composition and promote linear growth. Hexarelin and other GH secratogues show similar potential usefulness by clinical observations that long-term administration produces elevations in circulating IGF-1 concentrations. For example, significant increases in plasma IGF-1 concentrations were noted after 7 days of hexarelin infusion and have even been reported after 7 days of intranasal administration in children and in adults after 7 to 14 days of intranasal hexarelin administration. It is also of interest that long-term administration of hexarelin has been shown to significantly increase circulating GH concentrations as well. The potential clinical utility of these GH secratogues is due to the consistent clinical verification of these findings in individuals of many ages.